Caprioli Flavio, Pallone Francesco, Monteleone Giovanni
Dipartimento di Medicina, Interna, Università Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Inflamm Allergy Drug Targets. 2011 Feb;10(1):47-53. doi: 10.2174/187152811794352051.
In the gut of patients with Crohn's disease (CD), one of the major forms of inflammatory bowel diseases in humans, distinct subsets of T helper (Th) cells produce large amounts of cytokines, which are supposed to orchestrate the immuno-inflammatory process leading to the tissue damage. Indeed, cytokine blockers, including the three licensed anti-TNF-alpha and the neutralizing IL-12/p40 antibodies, have already been tested with success in CD. More than one third of patients do not respond to these treatments and response can wane with time. Moreover, blockade of such cytokines has been reported to associate with development of severe side effects and/or new immune-mediated pathologies. These findings and our better understanding of cytokine-associated effector pathways of tissue destruction suggest the necessity of novel cytokine-based therapies in CD.
在人类主要的炎症性肠病之一——克罗恩病（CD）患者的肠道中，不同亚群的辅助性T（Th）细胞会产生大量细胞因子，这些细胞因子被认为在协调导致组织损伤的免疫炎症过程中发挥作用。事实上，细胞因子阻滞剂，包括三种已获许可的抗TNF-α药物和中和性IL-12/p40抗体，已在CD治疗中取得成功。超过三分之一的患者对这些治疗无反应，且反应会随时间减弱。此外，据报道，阻断此类细胞因子会引发严重副作用和/或新的免疫介导疾病。这些发现以及我们对与细胞因子相关的组织破坏效应途径的深入理解表明，在CD治疗中采用新型细胞因子疗法很有必要。
